Drug discovery

Odyssey Therapeutics Announces Strategic Collaboration to Advance AI-Driven Small Molecule Drug Discovery

Retrieved on: 
Thursday, April 4, 2024
Biotechnology, Health, Pharmaceutical, Technology, Artificial Intelligence, Odyssey, Johnson & Johnson, Drug discovery, Patient, Artificial intelligence, Computational chemistry, Therapy, Machine learning, Pharmaceutical industry

Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision medicines, announced today it has entered into a strategic research collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, to jointly discover and optimize small molecule medicines against select therapeutic targets.

Key Points: 
  • Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision medicines, announced today it has entered into a strategic research collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, to jointly discover and optimize small molecule medicines against select therapeutic targets.
  • The companies will combine their expertise in artificial intelligence (AI), machine learning (ML), computational chemistry and drug discovery to unlock difficult-to-drug targets.
  • “We are excited about this collaboration to push the boundaries of the drug discovery and development process, using the latest advancements in AI and ML to find solutions for serious diseases,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics.
  • Odyssey will receive an upfront payment and is eligible for milestone payments and royalties.

Aurigene Pharmaceutical Services Ltd. introduces Aurigene.AI™, an artificial intelligence (AI) and machine learning (ML) assisted drug discovery platform

Retrieved on: 
Wednesday, April 3, 2024
Software, Biotechnology, Pharmaceutical, Health, Artificial Intelligence, Data Management, Health Technology, Technology, Cloud, Google Cloud, Algorithm, Database, Drug discovery, Drug, CADD, DMTA, AI, Assay, Confidentiality, Therapy, Machine learning, Medical device

Aurigene Pharmaceutical Services Limited (Aurigene), a contract research, development, and manufacturing services organization and a Dr. Reddy’s Laboratories company, introduces Aurigene.AI, an AI and ML-assisted platform for accelerating drug discovery projects from hit identification to candidate nomination.

Key Points: 
  • Aurigene Pharmaceutical Services Limited (Aurigene), a contract research, development, and manufacturing services organization and a Dr. Reddy’s Laboratories company, introduces Aurigene.AI, an AI and ML-assisted platform for accelerating drug discovery projects from hit identification to candidate nomination.
  • Aurigene.AI combines advanced physics-based simulation, generative and predictive AI models, and CADD (Computer-Aided Drug Design) in one platform, allowing users to pick the appropriate algorithms for a given application.
  • The modular platform also consists of a meticulously curated database of 180 million compounds and 1.6 million validated bioassay data points.
  • Akhil Ravi, CEO, Aurigene Pharmaceutical Services Ltd., said, “We are committed to continually advancing our service experience and providing innovative end-to-end solutions to our global partners.

Pharmacy Automation: Technologies and Global Markets Report 2024-2028 Featuring Major Players - BD, Baxter, Omnicell, and KUKA - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 3, 2024
Health, Pharmaceutical, RFID, Automation, Omnicell, Drug discovery, Internet of things, KUKA, ESG, Pharmacy, Internet, Artificial intelligence, Pharmacist, Workflow, Cloud computing, Growth, USD, Baxter, Approximation error

The "Pharmacy Automation: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmacy Automation: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The Global Pharmacy Automation Market was valued at USD 7.8 Billion in 2023, and is expected to reach USD 12.7 Billion by 2028, rising at a CAGR of 10.20%.
  • This report is designed to be a helpful business tool that will provide a thorough evaluation of the global pharmacy automation market.
  • Definitive and detailed estimates and forecasts of the global market are provided, followed by a detailed analysis of segments and regions.

Leading Clinical Research Innovator, Amy Abernethy, M.D., Ph.D., Joins insitro Board of Directors

Retrieved on: 
Wednesday, April 3, 2024
Technology, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, Data Management, Science, Artificial Intelligence, Principal, Hospice, Drug discovery, Intelligence, Patient, Software, Health policy, Duke Cancer Institute, Drug development, Machine learning, FDA, Medical device

insitro, a machine learning-powered drug discovery and development company, today announced that Amy Abernethy, M.D., Ph.D, has joined the company’s board of directors.

Key Points: 
  • insitro, a machine learning-powered drug discovery and development company, today announced that Amy Abernethy, M.D., Ph.D, has joined the company’s board of directors.
  • In that role, Dr. Abernethy oversaw the FDA’s vision and execution on the use of data and technology in clinical development.
  • There, she led teams in the development and delivery of software and data products that bridge the gap between clinical research and care.
  • “Amy has a career-long track record of leading high-impact initiatives that leverage clinical data to enable research and development, and accelerate the path of bringing medicines to patients,” said Daphne Koller, Ph.D., CEO and founder of insitro.

UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals

Retrieved on: 
Wednesday, April 3, 2024
Legal, Biotechnology, Pharmaceutical, Public Relations, Investor Relations, Health, FDA, Communications, Professional Services, The Orange Book, Drug discovery, Carcinoma, Patent, District court, Mitomycins, Orange Book, Food, Generic drug

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd., alleging infringement of U.S. Patent Numbers 9,040,074 (“the ’074 patent”) and 9,950,069 (“the ’069 patent”).

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd., alleging infringement of U.S. Patent Numbers 9,040,074 (“the ’074 patent”) and 9,950,069 (“the ’069 patent”).
  • Both patents are listed in the U.S. Food and Drug Administration’s (“FDA”) Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) for JELMYTO® (mitomycin) for pyelocalyceal solution.
  • JELMYTO® is indicated for the treatment of adults with low-grade, upper tract urothelial cancer (“LG-UTUC”) and utilizes UroGen’s RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology.
  • “UroGen pioneered a significant breakthrough and remains at the forefront of transforming urothelial cancer treatment,” said Liz Barrett, President and CEO, UroGen.

Alterome Therapeutics Raises $132 Million in Series B Financing Led by Goldman Sachs Alternatives

Retrieved on: 
Wednesday, April 3, 2024
Research, Finance, Clinical Trials, Professional Services, Biotechnology, Health, General Health, Science, Oncology, OrbiMed, Drug discovery, Patient, Cancer, Sachs, Blue Owl Capital, Protein, Medicine, Richard Driehaus, Therapy, Partner

Alterome Therapeutics, Inc. , a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the closing of a $132 million Series B financing.

Key Points: 
  • Alterome Therapeutics, Inc. , a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the closing of a $132 million Series B financing.
  • The financing was led by Goldman Sachs Alternatives, with participation by Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, and existing investors Orbimed, Nextech Invest, Vida Ventures, Boxer Capital, and Colt Ventures.
  • Concurrent with the financing, Josh Richardson, M.D., a Managing Director within Life Sciences Investing at Goldman Sachs Alternatives, and Uwe Schoenbeck, a Partner at Canaan Partners, were named to the Board of Directors.
  • “Alterome is advancing an exciting portfolio of therapies targeting validated oncogenic drivers, with clear paths to early clinical signals,” said Dr. Josh Richardson, Managing Director within Life Sciences Investing at Goldman Sachs Alternatives.

Nimble Therapeutics Expands its Drug Discovery Capabilities to Advance Pipeline to the Clinic

Retrieved on: 
Wednesday, April 3, 2024
Oncology, Health, Infectious Diseases, Radiology, Pharmaceutical, Biotechnology, Pfizer, De Montfort University, Drug discovery, Yale University, BU, Harvard University, Patient, Flavell, Immunology, Merck, Head, Wetzler, Merck & Co., IND, Rhône-Poulenc, Therapy, CSO, American Chemical Society, Medicinal chemistry, Peptide, Pharmaceutical industry

In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.

Key Points: 
  • In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.
  • Shelley Allen will join as Head of Drug Discovery and will lead the advanced optimization and characterization of clinical candidate peptides and their progression into the clinic.
  • Munir Mosaheb will join as Head of Biology and will lead the pharmacological, immunological and translational aspects of Nimble’s drug discovery programs.
  • She joined Nimble from Think Bioscience where she was VP, Medicinal Chemistry, and responsible for establishing drug discovery teams and capabilities to develop their internal programs.

Strategic Acquisition Opportunity: Biotechnology Intellectual Property of Civetta Therapeutics, LLC Now Open for Bids

Retrieved on: 
Thursday, April 4, 2024
Biotechnology, Pharmaceutical, Finance, Oncology, General Health, Health, Consulting, Professional Services, Interest, Drug discovery, Creditor, Inflammation, Acquisition, DSI, Therapy, Confidentiality, Intellectual property, Assignment (law), Collection, Civetta, Fine chemical

The Assignee of Civetta Therapeutics, LLC, a trailblazer in the field of biotechnology with a focus on β-propeller protein research, is inviting bids for the company's rich portfolio of intellectual property.

Key Points: 
  • The Assignee of Civetta Therapeutics, LLC, a trailblazer in the field of biotechnology with a focus on β-propeller protein research, is inviting bids for the company's rich portfolio of intellectual property.
  • The available intellectual property portfolio offers a unique opportunity to invest in a cutting-edge area of biotechnology.
  • This is a rare opportunity to acquire a comprehensive portfolio of intellectual property in a field with immense therapeutic and commercial potential.
  • Interested parties are invited to submit their bids for Civetta Therapeutics' intellectual property by April 30, 2024, 5:00 PM Central Time.

Odyssey Therapeutics Appoints Julie Clauss as Chief Operating Officer and Christopher Butler as SVP, Head of Chemistry

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, FDA, Health, General Health, Pharmaceutical, Oncology, Research, Infectious Diseases, Genetics, Science, Clinical Trials, Culture, Sanofi Pasteur, Drug discovery, Business administration, Patient, SVP, Gene, Joseph Fourier University, Standard of care, Cancer, University, Record, Inflammation, MBA, Therapy, Sloan Fellows, Research and development, Multimedia, Vertex Pharmaceuticals, Physical, Management

Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Julie Clauss, MBA, as chief operating officer and Christopher Butler, Ph.D., as senior vice president (SVP), head of Chemistry.

Key Points: 
  • Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Julie Clauss, MBA, as chief operating officer and Christopher Butler, Ph.D., as senior vice president (SVP), head of Chemistry.
  • Together, these individuals bring more than 40 years of leadership experience and scientific expertise within the biotechnology and pharmaceutical industries to Odyssey.
  • Clauss and Dr. Butler have proven track records of successfully leading teams to achieve strategic business and research goals.
  • Ms. Clauss received a Master of Business Administration through the Sloan Fellows program at the Massachusetts Institute of Technology.

Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs

Retrieved on: 
Tuesday, April 2, 2024
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Development, Carcinoma, Drug discovery, Patient, Neoplasm, Tumor microenvironment, CT155, DLL3, AACR, Immunity, HKEX, ADC, SCLC, Pharmaceutical industry

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that two poster presentations highlighting ongoing global clinical studies in its oncology pipeline will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024, in San Diego, California.

Key Points: 
  • Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that two poster presentations highlighting ongoing global clinical studies in its oncology pipeline will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024, in San Diego, California.
  • The global oncology programs to be showcased at AACR 2024 include a Phase 1a/1b study of ZL-1310 ( NCT06179069 ), a novel antibody-drug conjugate (ADC) within the Zai Lab pipeline that targets the Delta-like ligand 3 (DLL3), a validated therapeutic target for the treatment of small cell lung cancer (SCLC).
  • ZL-1310 is designed with a novel linker-payload platform TMALIN® which leverages the tumor microenvironment to overcome challenges associated with first-generation ADC therapies.
  • “These ongoing global clinical studies underscore Zai Lab’s continued commitment to pursue both novel and validated cancer biology targets and advance innovative oncology therapies that can potentially reach patients around the world,” said Rafael G. Amado, M.D., President, Head of Global Oncology Research and Development, Zai Lab.